SOURCE-LINKED STUDY SUMMARY
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
What was studied?
A blinded, randomized phase 1 trial evaluated eloralintide's safety, tolerability, drug exposure and effects in adults with overweight or obesity.
What changed?
Weight decreased 2.6–11.3% across eloralintide groups; the abstract provides no placebo-adjusted weight estimate. Events included decreased appetite, headache, fatigue and gastrointestinal symptoms, mostly mild. No deaths occurred; one serious event in the 6 mg cohort was considered unrelated.
Who was studied?
100 participants at three US centres averaged 44 years of age and a body mass index of 32.6; 29% were female.
Studied exposure
Weekly subcutaneous eloralintide or placebo for 12 weeks, without dose escalation within participants. Five dose cohorts were studied; the abstract identifies a 6 mg cohort but does not list all doses.
What remains uncertain?
Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.70439